10

What is claimed is:

1. A compound of the formula

 $R_rCH_2OP(halo)NR(CH_2)_nX$

wherein

5 R is C_1 - C_4 alkyl or - $(CH_2)_nX$;

n is 4 or 5;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom;

halo is chloro, bromo or iodo; and

the group R_rCH₂- is a biologically labile ester forming group.

- 2. The compound of claim 1 wherein n is 4.
- 3. The compound of claim 1 wherein n is 5.
- 4. The compound of claim 1 wherein R is methyl.
- 5. The compound of claim 1 wherein halo is chloro.
- 15 6. The compound of claim 1 wherein X is chloro or bromo.
 - 7. A method of preparing a phosphoramidate prodrug for enhanced intracellular delivery of a drug as phosphate ester or amide said method comprising the steps of reacting a hydroxy functional or amino functional drug compound (Drug-ZH) with a compound of the formula

 $R_rCH_2OP(halo)NR(CH_2)_nX$

under conditions conducive to the formation of an intermediate compound of the formula

R_rCH₂OP(Z-Drug)NR(CH₂)X

and oxidizing that intermediate to form the phosphoramidate prodrug of the formula

 $R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$

15

in which formulas

R is C_1 - C_4 alkyl or - $(CH_2)_nX$;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom;
halo is chloro, bromo or iodo; and

the group R_rCH₂- is a biologically labile ester forming group.

- 8. The method of claim 7 wherein Drug-ZH is an amino acid, or a biologically active peptide or peptidomimetic.
 - 9. The method of claim 8 wherein Drug-ZH is a peptidomimetic of the formula

$$HZ - (CH_2)_q[CHB]_kCONHCH(CH_3) - OCH_2 - OCH_2$$

wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino or C₁-C₄ alkanoylamino.

- 20 10. The method of claim 7 wherein Drug-ZH is a biologically active nucleotide analog.
 - 11. A phosphoramidate compound formed from a hydroxy functional or amino functional drug compound of the general formula Drug-ZH said prodrug being a compound of the formula

-64-

$R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$

wherein

R is C_1 - C_4 alkyl or - $(CH_2)_nX$;

n is 4 or 5;

5 Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced

from its bonded carbon atom;

halo is chloro, bromo or iodo; and

the group R_rCH₂- is a biologically labile ester forming group.

- 10 12. The prodrug of claim 11 wherein the drug is an amino acid, or a biologically active peptide or peptidomimetic.
 - 13. The method of claim 12 wherein Drug-ZH is a peptidomimetic of the formula

15
$$HZ$$
— $(CH_2)_q[CHB]_kCONHCH(CH_3)$ — OCH_2 — OCH_2

wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino or C₁-C₄ alkanoylamino.

- 14. The prodrug of claim 11 wherein the drug is a biologically active nucleotide analog.
 - 15. A method of preparing a compound of the formula

-65-

$R_rCH_2OP(O)_m(halo)NR(CH_2)_nX$

comprising the steps of reacting a compound of the formula

P(O)_mhalo₃

with 1) an alcohol of the formula R_rCH₂OH and 2) an amine of the formula HNR(CH₂)_nX, each in the presence of an acid scavenger,

wherein in the above formulas

m is 0 or 1;

R is C_1 - C_4 alkyl or - $(CH_2)_nX$;

n is 4 or 5;

10 X is an electrophilic group capable of being nucleophilically displaced

from its bonded carbon atom;

halo is chloro, bromo or iodo; and

the group R_rCH₂- is a biologically labile ester forming group.

16. A method of preparing a phosphoramidate prodrug of the formula

 $R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$

for enhanced intracellular delivery of a compound of the general formula Drug-ZPO. said method comprising the steps of reacting a hydroxy functional amino functional drug compound of the formula Drug-ZH with a compound of the formula

20 under conditions conducive to the formation of the prodrug

wherein in the above formulas

R is C_1 -C alkyl or -(CH_2)_nX;

n is 4 or 5;

Z is O or N;

5

15

-66-

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom;

halo is chloro, bromo or iodo; and

the group R_rCH₂- is a biologically labile ester forming group.

5 17. A pharmaceutical composition comprising

a phosphoramidate compound formed from a hydroxy functional or amino functional drug compound of the general formula Drug-ZH said prodrug being a compound of the formula

$$R_rCH_2OP(O)(Z-Drug)NR(CH_2)_nX$$

10 wherein

R is C_1 - C_4 alkyl or - $(CH_2)_nX$;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced

from its bonded carbon atom;

halo is chloro, bromo or iodo;

the group R_rCH₂- is a biologically labile ester forming group; and a pharmaceutically acceptable carrier therefor.

- The pharmaceutical compound of claim 17 wherein Drug-ZH is an amino
 acid or a biologically active peptide or peptidomimetic.
 - 19. The pharmaceutical composition of claim 18 wherein Drug-ZH is a peptidomimetic of the formula

The first that the first than the time and the first that the first that the first that the

10

$$\label{eq:conh2} \text{HZ--} \underbrace{\hspace{1cm}}^{\text{CONH}_2}_{\text{CCH}_2)_q} [\text{CHB}]_k \text{CONHCH(CH}_3) - \underbrace{\hspace{1cm}}^{\text{CONH}_2}_{\text{OCH}_2} - \underbrace{\hspace{1cm}}^{\text{CONH}_2}_{\text{OCH}_2}$$

5 wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino or C_1 - C_4 alkanoylamino.

20. The pharmaceutical composition of claim 17 wherein Drug-ZH is a nucleotide analog.